Compare CHMI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | RVPH |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 71.0M |
| IPO Year | 2013 | N/A |
| Metric | CHMI | RVPH |
|---|---|---|
| Price | $2.53 | $0.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.75 | ★ $3.33 |
| AVG Volume (30 Days) | 226.8K | ★ 8.4M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $134.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $0.25 |
| 52 Week High | $3.68 | $2.17 |
| Indicator | CHMI | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 30.55 |
| Support Level | $2.66 | $0.27 |
| Resistance Level | $2.78 | $0.34 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 19.84 | 9.85 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.